INS and type 1 diabetes mellitus: demonstrated anenhanced inhibitory capacity of Tregs, reduced fasting glucose, HbA1c and insulin dose(47) in 30 patients with new onsetstage 3 T1D assigned to cholecalciferol (70) IU/kg/day) vs. treatment with placebo for 12months, in association with insulin.